Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding
July 17, 2022
Share
Amicogen, Inc. announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 40,000,000,000 on July 18, 2022. The bonds will mature on July 20, 2027. The bonds are convertible into 1,622,520 common shares at a price of KRW 24,653 per share. The conversion period is from July 20, 2023 to June 20, 2027. The payment date is July 20, 2022. The transaction has been approved by the board of directors.
On October 20, 2022, the company announced that the bonds are convertible into 2,070,929 shares at a conversion price of KRW 19,315 per share.
On January 20, 2023, the company announced that the bonds are convertible into 2,041,545 shares at a conversion price of KRW 19,593 per share.
On April 20, 2023, the company announced that bond will be now convertible into 2,191,900 common shares of the company at a fixed conversion price of KRW 18,249 per share.
Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
AMICOGEN, INC. 